SLGL Profile
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, specializes in the development and commercialization of topical dermatological treatments utilizing its innovative microencapsulation delivery technology. Based in Ness Ziona, Israel, the company is focused on advancing its proprietary formulations to address a range of skin conditions through its advanced drug delivery system.
The company's leading product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream that has completed Phase III clinical trials for the treatment of acne vulgaris. Another key product is Epsolay, a once-daily topical cream which has also completed Phase III trials, targeting papulopustular rosacea. In addition to these, Sol-Gel is developing SGT-210, currently in Phase I trials for palmoplantar keratoderma. The company’s pipeline includes promising candidates such as Erlotinib, Tapinarof, and roflumilast, aimed at treating psoriasis and other dermatological conditions.
Sol-Gel Technologies Ltd. is also engaged in the development of generic topical dermatological products, expanding its portfolio to include cost-effective solutions for common skin disorders. This approach aligns with the company’s goal to offer a broad spectrum of dermatological treatments, leveraging its proprietary technology to enhance therapeutic efficacy and patient compliance.
Founded in 1997, Sol-Gel Technologies has established a strategic partnership with Perrigo, reflecting its commitment to advancing dermatological care through innovative solutions. The company’s dedication to research and development, combined with its expertise in microencapsulation technology, positions it as a significant player in the specialty pharmaceutical sector.
|
